Thermo Fisher Ponders Filling Edman Sequencer Gap; Is there Enough Demand? | GenomeWeb
Is Thermo Fisher Scientific poised to become the savior of N-terminal sequencers?
 
On the heels of Applied Biosystems’ pullout from the Edman sequencing market, which left the United States without a player in the space, Thermo Fisher is at least exploring the possibility of entering the arena by developing its own Edman sequencer or an alternative technology, a company official told ProteoMonitor last week.
 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Cell this week: phosphoproteomic patterns in prostate cancer, effect of gene expression on fitness in yeast, and more.

Scripps Research Institute investigators peer back at the RNA world.

Being born premature shouldn't mean infants with high blood sugar levels don't undergo genetic testing for neonatal diabetes, a study in Pediatrics says.

In PNAS this week: chromosome instability in S. cerevisiae, structural differences and sequence divergence in rice, and more.